Ho Carole
SEC CIK 1724605 · EDGAR
BoughtSold
Most active insiders at RPRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Coyne Terrance P. | EVP, CFO | — | $38.96M |
| 2 | Hite Christopher | EVP, Vice COB | — | $27.36M |
| 3 | Lloyd George W. | EVP, CLO, Investments | — | $13.81M |
| 4 | Urist Marshall | EVP, Research, Investments | — | $12.07M |
| 5 | Norden Gregory | Dir | — | $161.4K |
| 6 | Engelbert Catherine M. | Dir | — | — |
| 7 | Ho Carole | Dir | — | — |
| 8 | Coric Vlad | Dir | — | — |
| 9 | Bassler Bonnie L | Dir | — | — |
| 10 | Legorreta Pablo G. | CEO, COB, Dir | — | — |
Transactions 34
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 16:24 | 2026-06-05 | RPRX | Royalty Pharma plc | Ho Carole | Dir | A - Grant | $0.00 | +4,545 | 4,545 | New | $0 | |
| M | 2025-08-14 | 2025-08-12+ | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $13.81 | -3,743 | 217.4K | -2% | -$51.7K |
| D | 2025-08-07 | 2025-08-05 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | M - OptEx | $0.68 | +44.7K | 220.3K | +25% | +$30.4K |
| M | 2025-07-31 | 2025-07-31 | RPRX | Royalty Pharma plc | Ho Carole | Dir | A - Grant | $0.00 | +8,558 | 2,752 | New | $0 |
| M | 2025-01-08 | 2025-01-06+ | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $20.33 | -15.2K | 175.7K | -8% | -$308.3K |
| D | 2025-01-07 | 2025-01-03 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | A - Grant | $0.00 | +54.2K | 190.8K | +40% | $0 |
| D | 2024-11-27 | 2024-11-25 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | M - OptEx | $0.68 | +17.8K | 136.7K | +15% | +$12.1K |
| M | 2024-08-22 | 2024-08-20+ | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $24.49 | -22.5K | 118.8K | -16% | -$549.9K |
| 2024-08-15 | 2024-08-13 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $22.89 | -2,337 | 141.3K | -2% | -$53.5K | |
| M | 2024-02-15 | 2024-02-13+ | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $17.46 | -4,189 | 143.6K | -3% | -$73.1K |
| 2024-01-12 | 2024-01-10 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $19.02 | -4,668 | 147.8K | -3% | -$88.8K | |
| I | 2024-01-09 | 2024-01-05 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $19.43 | -9,972 | 198.8K | -5% | -$193.8K |
| D | 2024-01-05 | 2024-01-03 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | A - Grant | $0.00 | +53.7K | 162.4K | +49% | $0 |
| I | 2023-08-25 | 2023-08-23 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $23.22 | -2,522 | 182.8K | -1% | -$58.6K |
| I | 2023-08-23 | 2023-08-21 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $22.60 | -2,478 | 185.3K | -1% | -$56.0K |
| I | 2023-08-16 | 2023-08-14 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $23.79 | -2,768 | 182.8K | -1% | -$65.9K |
| I | 2023-08-14 | 2023-08-10 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $24.15 | -2,857 | 185.6K | -2% | -$69.0K |
| I | 2023-02-17 | 2023-02-15 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $29.40 | -1,476 | 182.8K | -0.8% | -$43.4K |
| MI | 2023-02-14 | 2023-02-10+ | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $30.03 | -3,366 | 184.3K | -2% | -$101.1K |
| I | 2023-02-10 | 2023-02-08 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $30.88 | -1,521 | 180.2K | -0.8% | -$47.0K |
| I | 2023-01-10 | 2023-01-09 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $28.48 | -1,459 | 177.5K | -0.8% | -$41.6K |
| MI | 2023-01-09 | 2023-01-05+ | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $28.52 | -4,087 | 178.9K | -2% | -$116.6K |
| D | 2023-01-05 | 2023-01-03 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | A - Grant | $0.00 | +41.1K | 139.0K | +42% | $0 |
| DI | 2023-01-05 | 2023-01-04 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $28.69 | -2,913 | 175.5K | -2% | -$83.6K |
| I | 2022-08-25 | 2022-08-23 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $31.98 | -2,424 | 170.7K | -1% | -$77.5K |
| I | 2022-08-23 | 2022-08-19 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $33.22 | -2,576 | 173.1K | -1% | -$85.6K |
| 2022-08-11 | 2022-08-09 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | A - Grant | $0.00 | +22.5K | 110.6K | +26% | $0 | |
| I | 2022-02-15 | 2022-02-11 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $34.71 | -2,918 | 170.7K | -2% | -$101.3K |
| I | 2022-02-11 | 2022-02-09 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $37.10 | -1,423 | 166.1K | -0.8% | -$52.8K |
| I | 2022-01-07 | 2022-01-05 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $44.78 | -2,845 | 163.3K | -2% | -$127.4K |
| D | 2022-01-05 | 2022-01-03 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | A - Grant | $0.00 | +31.0K | 107.3K | +41% | $0 |
| 2021-12-08 | 2021-12-06 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $42.52 | -1,476 | 76.3K | -2% | -$62.8K | |
| I | 2021-08-25 | 2021-08-23 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $48.91 | -6,143 | 158.6K | -4% | -$300.5K |
| MI | 2021-08-23 | 2021-08-19 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Off | S - Sale | $49.58 | -2,546 | 165.9K | -2% | -$126.2K |
Purchase Sale Sale after option exercise All abbreviations